Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling

Cancer Investigation

Volumn 28, Issue 8, 2010, Pages 775-787

  Hasselbalch, Benedikte ^a   Lassen, Ulrik ^a   Poulsen, Hans S ^a   Stockhausen, Marie Thérése ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Cetuximab; EGFR; Glioblastoma multiforme; Glioma; PTEN

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG MECHANISM; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL PROCESSING; WESTERN BLOTTING; CELL DIVISION; DRUG EFFECTS; DRUG RESISTANCE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; HEAD AND NECK TUMOR; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOHEXIMIDE; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77956631020     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.483506     Document Type: Article

References (53)

1. Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10), 987-996.
2. Kleihues, P.; Ohgaki, H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol 1999, 1(1), 44-51.
3. Kaur, B.; Tan, C.; Brat, D.J.; Post, D.E.; Van Meir, E.G. Genetic and hypoxic regulation of angiogenesis in gliomas. J Neuro Oncol 2004, 70(2), 229-243.
4. Kita, D.; Yonekawa, Y.;Weller, M.; Ohgaki, H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol (Berl) 2007, 113(3), 295-302.
5. Ekstrand, A.J.; James, C.D.; Cavenee, W.K.; Seliger, B.; Pettersson, R.F.; Collins, V.P. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991, 51(8), 2164-2172.
6. Smith, J.S.; Tachibana, I.; Passe, S.M.; Huntley, B.K.; Borell, T.J.; Iturria, N.; OFallon, J.R.; Schaefer, P.L.; Scheithauer, B.W.; James, C.D.; Buckner, J.C.; Jenkins, R.B. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93(16), 1246-1256.
7. Wikstrand, C.J.;McLendon, R.E.; Friedman, A.H.; Bigner, D.D. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997, 57(18), 4130-4140.
8. Alroy, I.; Yarden, Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410(1), 83-86.
9. Stokoe, D.; Stephens, L.R.; Copeland, T.; Gaffney, P.R.; Reese, C.B.; Painter, G.F.; Holmes, A.B.; McCormick, F.; Hawkins, P.T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277(5325), 567-570.
10. Choe, G.; Horvath, S.; Cloughesy, T.F.; Crosby, K.; Seligson, D.; Palotie, A.; Inge, L.; Smith, B.L.; Sawyers, C.L.; Mischel, P.S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003, 63(11), 2742-2746.
11. Osaki, M.; Oshimura, M.; Ito, H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9(6), 667-676.
12. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4), 337-345. (Pubitemid 38944402)
13. Rocha-Lima, C.M.; Soares, H.P.; Raez, L.E.; Singal, R. EGFR targeting of solid tumors. Cancer Control 2007, 14(3), 295-304.
14. Shirai, K.; OBrien, P.E. Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol 2007, 8(3), 239-251.
15. Rich, J.N.; Reardon, D.A.; Peery, T.; Dowell, J.M.; Quinn, J.A.; Penne, K.L.;Wikstrand, C.J.; Van Duyn, L.B.; Dancey, J.E.; McLendon, R.E.; Kao, J.C.; Stenzel, T.T.; Ahmed Rasheed, B.K.; Tourt-Uhlig, S.E.; Herndon, J.E.; Vredenburgh, J.J.; Sampson, J.H.; Friedman, A.H.; Bigner, D.D.; Friedman, H.S. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22(1), 133-142.
16. Quan, A.L.; Barnett, G.H.; Lee, S.Y.; Vogelbaum, M.A.; Toms, S.A.; Staugaitis, S.M.; Prayson, R.A.; Peereboom, D.M.; Stevens, G.H.; Cohen, B.H.; Suh, J.H. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2005, 63(3), 695-703.
17. Lassman, A.B.; Rossi, M.R.; Razier, J.R.; Abrey, L.E.; Lieberman, F.S.; Grefe, C.N.; Lamborn, K.; Pao, W.; Shih, A.H.; Kuhn, J.G.; Wilson, R.; Nowak, N.J.; Cowell, J.K.; DeAngelis, L.M.; Wen, P.; Gilbert, M.R.; Chang, S.; Yung, W.A.; Prados, M.; Holland, E.C. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005, 11(21), 7841-7850.
18. Franceschi, E.; Cavallo, G.; Lonardi, S.; Magrini, E.; Tosoni, A.; Grosso, D.; Scopece, L.; Blatt, V.; Urbini, B.; Pession, A.; Tallini, G.; Crino, L.; Brandes, A.A. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007, 96(7), 1047-1051.
19. Haas-Kogan, D.A.; Prados, M.D.; Tihan, T.; Eberhard, D.A.; Jelluma, N.; Arvold, N.D.; Baumber, R.; Lamborn, K.R.; Kapadia, A.; Malec, M.; Berger, M.S.; Stokoe, D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97(12), 880-887.
20. Mellinghoff, I.K.; Wang, M.Y.; Vivanco, I.; Haas-Kogan, D.A.; Zhu, S.; Dia, E.Q.; Lu, K.V.; Yoshimoto, K.; Huang, J.H.; Chute, D.J.; Riggs, B.L.; Horvath, S.; Liau, L.M.; Cavenee, W.K.; Rao, P.N.; Beroukhim, R.; Peck, T.C.; Lee, J.C.; Sellers, W.R.; Stokoe, D.; Prados,M.; Cloughesy, T.F.; Sawyers, C.L.; Mischel, P.S.Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353(19), 2012-2024.
21. Liu, W.; James, C.D.; Frederick, L.; Alderete, B.E.; Jenkins, R.B. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 1997, 57(23), 5254-5257.
22. Sano, T.; Lin, H.; Chen, X.; Langford, L.A.; Koul, D.; Bondy, M.L.; Hess, K.R.; Myers, J.N.; Hong, Y.K.; Yung, W.K.; Steck, P.A. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999, 59(8), 1820-1824.
23. Bianco, R.; Shin, I.; Ritter, C.A.; Yakes, F.M.; Basso, A.; Rosen, N.; Tsurutani, J.; Dennis, P.A.; Mills, G.B.; Arteaga, C.L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22(18), 2812-2822.
24. Mellinghoff, I.K.; Cloughesy, T.F.; Mischel, P.S. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007, 13(2 Pt 1), 378-381.
25. Li, S.; Schmitz, K.R.; Jeffrey, P.D.; Wiltzius, J.J.; Kussie, P.; Ferguson, K.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7(4), 301-311.
26. Goldstein, N.I.; Prewett, M.; Zuklys, K.; Rockwell, P.; Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995, 1(11), 1311-1318.
27. Rivera, F.; Vega-Villegas, M.E.; Lopez-Brea, M.F. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008, 19(2), 99-113.
28. Eller, J.L.; Longo, S.L.; Hicklin, D.J.; Canute, G.W. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 2002, 51(4), 1005-1013.
29. Eller, J.L.; Longo, S.L.; Kyle, M.M.; Bassano, D.; Hicklin, D.J.; Canute, G.W. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005, 56(1), 155-162.
30. Combs, S.E.; Schulz-Ertner, D.; Roth, W.; Herold-Mende, C.; Debus, J.; Weber, K.J. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007, 68(3), 873-882.
31. Filmus, J.; Pollak, M.N.; Cairncross, J.G.; Buick, R.N. Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 1985, 131(1), 207-215.
32. Huang, S.M.; Bock, J.M.; Harari, P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59(8), 1935-1940.
33. Ullrich, A.; Coussens, L.; Hayflick, J.S.; Dull, T.J.; Gray, A.; Tam, A.W.; Lee, J.; Yarden, Y.; Libermann, T.A.; Schlessinger, J. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984, 309(5967), 418-425.
34. Pandita, A.; Aldape, K.D.; Zadeh, G.; Guha, A.; James, C.D. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004, 39(1), 29-36.
35. Ishii, N.; Maier, D.; Merlo, A.; Tada, M.; Sawamura, Y.; Diserens, A.C.; Van Meir, E.G. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999, 9(3), 469-479.
36. Sunada, H.; Magun, B.E.; Mendelsohn, J.; MacLeod, C.L. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 1986, 83(11), 3825-3829.
37. Perez-Torres, M.; Guix, M.; Gonzalez, A.; Arteaga, C.L. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 2006, 281(52), 40183-40192.
38. Jaramillo, M.L.; Leon, Z.; Grothe, S.; Paul-Roc, B.; Abulrob, A.; OConnor, M.M. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 2006, 312(15), 2778-2790.
39. Andersen, P.; Pedersen, M.W.; Woetmann, A.; Villingshoj, M.; Stockhausen, M.T.; Odum, N.; Poulsen, H.S. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer 2008, 122(2), 342-349.
40. Fukai, J.; Nishio, K.; Itakura, T.; Koizumi, F. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 2008, 99(10), 2062-2069.
41. Lokker, N.A.; Sullivan, C.M.; Hollenbach, S.J.; Israel, M.A.; Giese, N.A. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002, 62(13), 3729-3735.
42. Chakravarti, A.; Loeffler, J.S.; Dyson, N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62(1), 200-207.
43. Lievre, A.; Bachet, J.B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.F.; Cote, J.F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66(8), 3992-3995.
44. Lymbouridou, R.; Soufla, G.; Chatzinikola, A.M.; Vakis, A.; Spandidos, D.A. Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer 2009.
45. Martens, T.; Laabs, Y.; Gunther, H.S.; Kemming, D.; Zhu, Z.; Witte, L.; Hagel, C.; Westphal, M.; Lamszus, K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin Cancer Res 2008, 14(17), 5447-5458.
46. Hasselbalch, B.; Lassen, U.; Hansen, S.; Holmberg, M.; Sorensen, M.; Kosteljanetz, M.; Broholm, H.; Stockhausen, M.T.; Poulsen, H.S. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010, 12(5), 508-516.
47. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E.; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30), 4722-4729. (Pubitemid 350086473)
48. Prados, M.D.; Lamborn, K.; Yung, W.K.; Jaeckle, K.; Robins, H.I.; Mehta, M.; Fine, H.A.; Wen, P.Y.; Cloughesy, T.; Chang, S.; Nicholas, M.K.; Schiff, D.; Greenberg, H.; Junck, L.; Fink, K.; Hess, K.; Kuhn, J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 2006, 8(2), 189-193. (Pubitemid 46542664)
49. Fan, Q.W.; Cheng, C.K.; Nicolaides, T.P.; Hackett, C.S.; Knight, Z.A.; Shokat, K.M.; Weiss, W.A. A dual phosphoinositide-3-kinase {alpha}/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007, 67(17), 7960-7965.
50. Stommel, J.M.; Kimmelman, A.C.; Ying, H.; Nabioullin, R.; Ponugoti, A.H.;Wiedemeyer, R.; Stegh, A.H.; Bradner, J.E.; Ligon, K.L.; Brennan, C.; Chin, L.; DePinho, R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318(5848), 287-290.
51. Zandi, R.; Larsen, A.B.; Andersen, P.; Stockhausen, M.T.; Poulsen, H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007, 19(10), 2013-2023.
52. Doody, J.F.;Wang, Y.; Patel, S.N.; Joynes, C.; Lee, S.P.; Gerlak, J.; Rolser, R.L.; Li, Y.; Steiner, P.; Bassi, R.; Hicklin, D.J.; Hadari, Y.R. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007, 6(10), 2642-2651.
53. Patel, D.; Lahiji, A.; Patel, S.; Franklin, M.; Jimenez, X.; Hicklin, D.J.; Kang, X. Monoclonal antibody cetuximab binds to and downregulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007, 27(5A), 3355-3366.